PDE5A and angina pectoris: The results of the studies presented by Terentes-Printzios D. et al. and Yannas D. et al. emphasize that in patients with erectile dysfunction at high cardiovascular risk, the cardiologist is responsible for intensive risk factor control and safety assessment of pharmacotherapy, including PDE-5 inhibitors, which remain contraindicated in unstable angina [23,24].